Literature DB >> 29604336

Mast cell disorders: Protean manifestations and treatment responses.

Meng Chen1, Alexander Kim1, Bruce Zuraw2, Taylor A Doherty1, Sandra Christiansen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29604336      PMCID： PMC6026564          DOI： 10.1016/j.anai.2018.03.027

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  10 in total

1.  Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.

Authors:  Line Kibsgaard; Tina Skjold; Mette Deleuran; Christian Vestergaard
Journal:  Acta Derm Venereol       Date:  2014-05       Impact factor: 4.437

Review 2.  Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome.

Authors:  Mahmoud Abdelghany; Rogin Subedi; Siddharth Shah; Hani Kozman
Journal:  Int J Cardiol       Date:  2017-01-27       Impact factor: 4.164

Review 3.  Mast Cells, Mastocytosis, and Related Disorders.

Authors:  Theoharis C Theoharides; Peter Valent; Cem Akin
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

Review 4.  Mast cell activation syndromes.

Authors:  Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

5.  Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

Authors:  Amanda Jagdis; Peter Vadas
Journal:  Ann Allergy Asthma Immunol       Date:  2014-07       Impact factor: 6.347

6.  Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.

Authors:  Anupama Ravi; Joseph Butterfield; Catherine R Weiler
Journal:  J Allergy Clin Immunol Pract       Date:  2014-11-06

7.  Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.

Authors:  Animesh Pardanani
Journal:  Am J Hematol       Date:  2016-11       Impact factor: 10.047

8.  Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.

Authors:  Matthew C Bell; Daniel J Jackson
Journal:  Ann Allergy Asthma Immunol       Date:  2012-03-21       Impact factor: 6.347

9.  Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.

Authors:  Benjamin D McNeil; Priyanka Pundir; Sonya Meeker; Liang Han; Bradley J Undem; Marianna Kulka; Xinzhong Dong
Journal:  Nature       Date:  2014-12-17       Impact factor: 49.962

10.  Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.

Authors:  Sofie Lieberoth; Simon Francis Thomsen
Journal:  Case Rep Med       Date:  2015-01-28
  10 in total
  1 in total

1.  Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis.

Authors:  Noelia Dasilva-Freire; Andrea Mayado; Cristina Teodosio; María Jara-Acevedo; Iván Álvarez-Twose; Almudena Matito; Laura Sánchez-Muñoz; Carolina Caldas; Ana Henriques; Javier I Muñoz-González; Andrés C García-Montero; J Ignacio Sánchez-Gallego; Luis Escribano; Alberto Orfao
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.